Batmunkh Tsetsegsaikhan, von Mollendorf Claire, Tulgaa Khosbayar, Surenjav Unursaikhan, Dalmau Marguerite T, Namjil Narantuya, Tsedevdamba Battsetseg, Tsegmed Sambuu, Enkhmaa Jalserd, Garland Suzanne M, Mulholland Kim
National Cancer Council of Mongolia, #101, Oyutnii Khotkhon 68/1, Bayanzurkh District, Ulaanbaatar, Mongolia.
Murdoch Children's Research Institute, 50 Flemington Road, Parkville, Melbourne, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Melbourne, Australia.
Papillomavirus Res. 2019 Dec;8:100175. doi: 10.1016/j.pvr.2019.100175. Epub 2019 Jul 2.
In a 2012 pilot, 9111 Mongolian girls aged 11-17 years received three doses of the quadrivalent (4vHPV) vaccine, Gardasil. This is the first study to measure early vaccine effectiveness and assess knowledge and attitudes of young women in Mongolia in relation to the human papillomavirus (HPV), the vaccine and cervical cancer.
A cohort of women vaccinated in 2012 (n = 726) and an unvaccinated cohort (n = 790) provided self-administered vaginal swabs for detection of high-risk HPV genotypes 16, 18/45, 31, 33, 35, 39, 51, 52, 56, 58, 59, 66, 68 five years following vaccination. Participant knowledge and attitudes were assessed through a questionnaire.
A total of 1882 questionnaires and 1516 self-administered vaginal swabs were analyzed. The prevalence of any HRHPV was 39.5% among both cohorts. The prevalence of vaccine-targeted HPV types was significantly lower in the vaccinated cohort than unvaccinated: 4.8% and 17.2% respectively. The 4vHPV was shown to be protective against HRHPV 16, 18/45 with 75% vaccine effectiveness. Participant knowledge was low.
This study demonstrates that the 4vHPV is associated with reduced vaccine-targeted HPV detection rates in young Mongolian women. The questionnaire results highlight a need for awareness-raising initiatives in Mongolia on HPV, the vaccine and cervical cancer.
在2012年的一项试点研究中，9111名年龄在11至17岁的蒙古女孩接种了三剂四价（4vHPV）疫苗佳达修。这是第一项测量早期疫苗效力并评估蒙古年轻女性对人乳头瘤病毒（HPV）、该疫苗和宫颈癌的知识及态度的研究。
2012年接种疫苗的一组女性（n = 726）和未接种疫苗的一组女性（n = 790）在接种疫苗五年后自行采集阴道拭子，用于检测高危HPV基因型16、18/45、31、33、35、39、51、52、56、58、59、66、68。通过问卷调查评估参与者的知识和态度。
共分析了1882份问卷和1516份自行采集的阴道拭子。两个队列中任何高危型人乳头瘤病毒（HRHPV）的患病率均为39.5%。接种疫苗队列中疫苗针对的HPV类型的患病率显著低于未接种疫苗的队列：分别为4.8%和17.2%。4vHPV疫苗对HRHPV 16、18/45显示出75%的疫苗效力。参与者的知识水平较低。
本研究表明，4vHPV与蒙古年轻女性中疫苗针对的HPV检测率降低有关。问卷调查结果凸显了蒙古需要开展关于HPV、该疫苗和宫颈癌的提高认识倡议。
